/
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
The business is unprofitable at the operating level (-145637.52% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 51.8% YoY. Margins deteriorated 137032.1pp alongside, both lines moving the wrong way.
ROIC dropped from -22824.17% to -23806.36%, capital efficiency is deteriorating. Negative free cash flow of -$21M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$40K
▼ -51.8% YoY
Net Income (TTM)
-$39M
▼ -422.3% YoY
Op. Margin
-145637.52%
▼ -137032.1pp YoY
ROIC
-7120.15%
▼ -982.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$22M
▼ -395.1% YoY
Op. Cash Flow (TTM)
-$22M
▼ -383.3% YoY
Net Debt
$207K
Cash & Equiv.
$139K
Continue Research